

Management of atrial fibrillation in seven European countries: a comparison with the 2010 ESC Guidelines on atrial fibrillation: primary results of the European Registry in Atrial Fibrillation (EURO-RAF) study

Europace

16, 6-14

DOI: [10.1093/europace/eut263](https://doi.org/10.1093/europace/eut263)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
3	Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 12, 3-8.	0.4	19
4	Differences among western European countries in anticoagulation management of atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 833-841.	1.8	96
5	DIAGNOSTICS, TREATMENT, ASSOCIATED CARDIOVASCULAR AND CONCOMITANT NON-CARDIAC DISEASES IN PATIENTS WITH DIAGNOSIS OF "ATRIAL FIBRILLATION" IN REAL OUTPATIENT PRACTICE (ACCORDING TO DATA). <i>TJ ETQq1 1 0.7843142987 / Over</i> 10, 366-377.	0.3	30
6	Atrial fibrillation in the elderly: a review. <i>Future Cardiology</i> , 2014, 10, 745-758.	0.5	10
7	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	1.0	154
8	Electrocautery-induced ventricular fibrillation during routine implantable cardioverter-defibrillator generator replacement. <i>Europace</i> , 2014, 16, 319-319.	0.7	3
9	'Preferred' management of atrial fibrillation in Europe. <i>Europace</i> , 2014, 16, 1-3.	0.7	38
10	The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. <i>Europace</i> , 2014, 16, 965-972.	0.7	161
11	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) <i>TJ ETQq1 1 0.7843142987 / Over</i>	0.7	161
12	Prevalência da anticoagulação oral em doentes com fibrilhação auricular em Portugal: revisão sistemática e meta-análise de estudos observacionais. <i>Revista Portuguesa De Cardiologia</i> , 2014, 33, 555-560.	0.2	16
13	Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2014, 9, 861-870.	1.0	27
14	Perioperative challenges of atrial fibrillation. <i>Current Opinion in Anaesthesiology</i> , 2014, 27, 344-352.	0.9	38
15	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. <i>Europace</i> , 2014, 16, 1397-1416.	0.7	259
16	Use of Antithrombotic Therapy in Patients With Atrial Fibrillation in Primary Care. Importance of INR Control. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 420.	0.4	0
17	Uso del tratamiento antitrombótico en pacientes con fibrilación auricular en atención primaria. Importancia del control del INR. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 420.	0.6	0
19	Use of anticoagulants for atrial fibrillation in older subjects across different countries: Cyprus, France, Netherlands, Norway. <i>European Geriatric Medicine</i> , 2014, 5, 60-65.	1.2	3
21	Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the International RealiseAF Survey. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 77-87.	0.7	81

#	ARTICLE	IF	CITATIONS
22	Of hammers and screws: renin-angiotensin-aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension. <i>European Heart Journal</i> , 2014, 35, 1169-1171.	1.0	13
23	â€œReal-Worldâ€™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. <i>American Journal of Medicine</i> , 2014, 127, 519-529.e1.	0.6	144
24	Atrial fibrillation: state of the art. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 692-704.	1.0	0
25	The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey. <i>Eurpace</i> , 2014, 16, 1720-1725.	0.7	60
26	Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	39
27	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014, 100, 1625-1635.	1.2	27
28	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490
29	Use of Antithrombotic Therapy in Patients With Atrial Fibrillation in Primary Care. Importance of INR Control. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 419.	0.4	0
30	Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: Insights from the RealiseAF Taiwanese cohort. <i>Journal of Cardiology</i> , 2014, 64, 211-217.	0.8	13
31	Uso del tratamiento antitrombÃ³tico en pacientes con fibrilaciÃ³n auricular en atenciÃ³n primaria. Importancia del control del INR. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 419.	0.6	2
32	Continued commitment to safety: building on the existing rivaroxaban knowledge base: TableÃ1. <i>European Heart Journal Supplements</i> , 2015, 17, D21-D28.	0.0	0
33	Why do we need observational studies of everyday patients in the real-life setting?: TableÃ1. <i>European Heart Journal Supplements</i> , 2015, 17, D2-D8.	0.0	101
36	Directâ€œacting oral anticoagulants: pharmacology, indications, management, and future perspectives. <i>European Journal of Haematology</i> , 2015, 95, 389-404.	1.1	70
37	Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. <i>Chest</i> , 2015, 148, 62-72.	0.4	40
38	Do CHA ₂ DS ₂ VASc and HAS-BLED scores influence â€œrealâ€™worldâ€™ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1297-1303.	0.9	6
39	Triple therapy for atrial fibrillation and percutaneous coronary intervention. <i>Current Opinion in Cardiology</i> , 2015, 30, 690-696.	0.8	1
40	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. <i>PLoS ONE</i> , 2015, 10, e0124719.	1.1	50
41	Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. <i>International Journal of General Medicine</i> , 2015, 8, 231.	0.8	43

#	ARTICLE	IF	CITATIONS
42	Oral anticoagulant therapy for atrial fibrillation in patients with coronary heart disease. Journal of the Japanese Coronary Association, 2015, 21, 234-238.	0.0	0
43	Cardioversion in Non-Valvular Atrial Fibrillation. Deutsches Arzteblatt International, 2015, 112, 856-62.	0.6	15
44	Effect of Early Direct Current Cardioversion on the Recurrence of Atrial Fibrillation in Patients With Persistent Atrial Fibrillation. American Journal of Cardiology, 2015, 116, 225-229.	0.7	6
45	Asian strategy for stroke prevention in atrial fibrillation. Europace, 2015, 17, ii31-ii39.	0.7	36
46	Análisis coste-efectividad de apixabán frente a acenocumarol en la prevención del ictus en pacientes con fibrilación auricular no valvular en España. Revista Espanola De Cardiologia, 2015, 68, 680-690.	0.6	22
47	The state of oral anticoagulant therapy in patients with atrial fibrillation in Spain. Revista Clinica Espanola, 2015, 215, 100-101.	0.2	0
48	Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain. Revista Espanola De Cardiologia (English Ed), 2015, 68, 680-690.	0.4	14
49	Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?. Internal and Emergency Medicine, 2015, 10, 21-24.	1.0	4
50	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. European Journal of Internal Medicine, 2015, 26, e31-e33.	1.0	2
51	Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: Perspectives from the observational, prospective WATER Registry. Cardiology Journal, 2015, 22, 567-575.	0.5	15
52	Patients with atrial fibrillation and CHA2DS2-VASc score 1: "To anticoagulate or not to anticoagulate? That is the question!" Heart Rhythm, 2015, 12, 2515-2520.	0.3	5
53	Valvular heart disease among non-valvular atrial fibrillation: a misnomer, in search of a new term. European Heart Journal, 2015, 36, 1794-1797.	1.0	14
54	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace, 2015, 17, 1007-1017.	0.7	46
55	New oral anticoagulants: a practical guide for physicians. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 134-145.	1.4	54
56	Therapeutic management in ambulatory elderly patients with atrial fibrillation: The S.AGES cohort. Journal of Nutrition, Health and Aging, 2015, 19, 219-227.	1.5	7
57	Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace, 2015, 17, 507-508.	0.7	20
58	Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF study. Revista Clinica Espanola, 2015, 215, 73-82.	0.3	5
59	A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark. Pharmacoeconomics, 2015, 33, 967-979.	1.7	15

#	ARTICLE	IF	CITATIONS
60	Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non-Valvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2015, 4, e001486.	1.6	171
61	Efficacy and Safety of Oral Anticoagulants Versus Aspirin for Patients With Atrial Fibrillation. <i>Medicine (United States)</i> , 2015, 94, e409.	0.4	15
62	New oral anticoagulants versus vitamin K antagonists before cardioversion of atrial fibrillation: a meta-analysis of data from 4 randomized trials. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 577-583.	0.6	5
63	Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 476-484.	1.1	27
64	Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry. <i>BMC Neurology</i> , 2015, 15, 129.	0.8	22
65	Stroke prevention in atrial fibrillation: evidence from real-life studies: Table A1. <i>European Heart Journal Supplements</i> , 2015, 17, D42-D52.	0.0	4
66	Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 544-553.	0.7	17
68	Oral anticoagulation after catheter ablation of atrial fibrillation: caught in the attribution trap?. <i>European Heart Journal</i> , 2015, 36, 267-269.	1.0	5
69	Situación del tratamiento anticoagulante oral en pacientes con fibrilación auricular no valvular en España. Estudio REACT-AF. <i>Revista Clinica Espanola</i> , 2015, 215, 73-82.	0.2	20
70	Antiplatelet therapy is not a safer alternative to oral anticoagulants, even in older hospital-discharged patients with atrial fibrillation. <i>Geriatric Care</i> , 2016, 2, .	0.2	1
71	Practical Guide to the New Oral Anticoagulants. <i>Journal of General Practice (Los Angeles, Calif)</i> , 2016, 03, .	0.1	0
72	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, qcw058.	1.8	27
73	Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1076-1083.	1.1	12
74	Acenocoumarol vs. low-dose dabigatran in real-world patients discharged after ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 185-189.	0.5	1
75	Anticoagulation in atrial fibrillation and chronic heart failure. <i>Current Opinion in Cardiology</i> , 2016, 31, 229-234.	0.8	9
76	Perindopril for the prevention of atrial fibrillation recurrence after radiofrequency catheter ablation: One-year experience. <i>Heart Rhythm</i> , 2016, 13, 2040-2047.	0.3	10
77	Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database. <i>BMJ Open</i> , 2016, 6, e010144.	0.8	8
78	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 893-952.	0.8	113

#	ARTICLE	IF	CITATIONS
79	Stroke prevention in atrial fibrillation and "real world" adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. <i>Scientific Reports</i> , 2016, 6, 20432.	1.6	40
80	La fibrilaci3n auricular en las guAas de prActica clAnica. <i>Revista Espanola De Cardiologia Suplementos</i> , 2016, 16, 52-54.	0.2	0
81	Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 299-305.	1.8	31
82	Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	143
83	Optimal antithrombotic treatment in patients with atrial fibrillation and coronary stents. <i>Current Opinion in Cardiology</i> , 2016, 31, 356-365.	0.8	1
84	The Risk of Hospital Admission Due to Traumatic Brain Injury Is Increased in Older Persons With Severe Functional Limitations. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 609-612.	1.2	11
86	Anticoagulation management in non-valvular atrial fibrillation in rural and remote Crete. A single-center study from the region of Sitia. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 279-281.	0.4	8
87	Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. <i>Pharmacological Research</i> , 2016, 113, 484-489.	3.1	22
88	New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. <i>Clinical Cardiology</i> , 2016, 39, 739-746.	0.7	15
89	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	0.6	754
90	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1413-1447.	1.4	10
91	New oral anticoagulants versus Warfarin in patients undergoing cardioversion of atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 225, 244-246.	0.8	5
92	Overcoming global challenges in stroke prophylaxis in atrial fibrillation: The role of non-vitamin K antagonist oral anticoagulants. <i>International Journal of Stroke</i> , 2016, 11, 950-967.	2.9	2
93	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
94	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
95	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. <i>Circulation Journal</i> , 2016, 80, 2102-2108.	0.7	21
96	Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire. <i>International Journal of Cardiology</i> , 2016, 223, 906-914.	0.8	65
97	Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. <i>Europace</i> , 2016, 18, 1507-1513.	0.7	7

#	ARTICLE	IF	CITATIONS
98	Changes in Oral Anticoagulant Treatment Rates in Atrial Fibrillation before and after the Introduction of Direct Oral Anticoagulants. <i>Neuroepidemiology</i> , 2016, 47, 201-209.	1.1	9
99	Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation. <i>Medicine (United States)</i> , 2016, 95, e5581.	0.4	15
100	Pacientes con anticoagulaci3n oral supervisados en consultas de atenci3n primaria: estudio en un centro de salud. <i>Medicina General Y De Familia</i> , 2016, 5, 91-96.	0.1	0
101	Clinical follow-up of atrial-fibrillation patients treated with novel oral anti-coagulants: A multi-disciplinary consensus from the Apulia section of the Italian Association of Hospital Cardiologists (ANMCO). <i>International Journal of Cardiology</i> , 2016, 202, 265-272.	0.8	3
102	Treatment with oral anticoagulant drugs restrained from patients with atrial fibrillation: An assessment in a geographically well-defined catchment area. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1437-1443.	0.8	3
103	Individualized approaches to thromboprophylaxis in atrial fibrillation. <i>American Heart Journal</i> , 2016, 173, 143-158.	1.2	12
104	Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. <i>Nature Reviews Cardiology</i> , 2016, 13, 230-237.	6.1	122
105	Effects of Oral Anticoagulant Therapy in Medical Inpatients 65 Years With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2016, 117, 590-595.	0.7	17
106	The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 90-94.	1.4	15
107	Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. <i>Europace</i> , 2016, 18, 463-467.	0.7	49
108	Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 183-200.	1.0	72
109	Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. <i>American Heart Journal</i> , 2016, 176, 10-16.	1.2	9
110	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	0.7	121
111	An update on atrial fibrillation in 2014: From pathophysiology to treatment. <i>International Journal of Cardiology</i> , 2016, 203, 22-29.	0.8	56
112	Current Antiarrhythmic Therapy for Nonvalvular Atrial Fibrillation in Spain. Data From the FANTASIA Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 54-60.	0.4	12
113	Tratamiento antiarrtmico actual de la fibrilaci3n auricular no valvular en Espa3a. Datos del Registro FANTASIA. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 54-60.	0.6	20
114	Effects of oral anticoagulant therapy in older medical in-patients with atrial fibrillation: a prospective cohort observational study. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 491-497.	1.4	14
115	Catheter ablation in patients with persistent atrial fibrillation. <i>European Heart Journal</i> , 2017, 38, 20-26.	1.0	103

#	ARTICLE	IF	CITATIONS
116	Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. <i>European Heart Journal</i> , 2017, 38, ehw564.	1.0	151
117	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 409-419.	1.2	67
119	Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention. <i>European Journal of Internal Medicine</i> , 2017, 40, 1-7.	1.0	5
120	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , 2017, 232, 98-104.	0.8	16
121	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017, 103, 1024-1030.	1.2	104
122	Triple antithrombotic therapy, including NAO, in patients after coronary stenting. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e125-e128.	0.6	0
123	Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 875-883.	0.9	10
124	Criteria for the choice of anticoagulant therapy for the prevention of stroke in patients with atrial fibrillation early after the marketing of direct oral anticoagulants in Italy. <i>European Journal of Internal Medicine</i> , 2017, 41, e12-e14.	1.0	1
125	Propafenone for supraventricular arrhythmias in septic shock – Comparison to amiodarone and metoprolol. <i>Journal of Critical Care</i> , 2017, 41, 16-23.	1.0	29
126	The future of atrial fibrillation management: integrated care and stratified therapy. <i>Lancet</i> , 2017, 390, 1873-1887.	6.3	128
127	Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants. <i>American Journal of Cardiology</i> , 2017, 120, 786-791.	0.7	30
128	Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review. <i>International Journal of Cardiology</i> , 2017, 243, 263-269.	0.8	9
129	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. <i>EBioMedicine</i> , 2017, 18, 199-203.	2.7	18
130	LAA occluder device for stroke prevention: Data on WATCHMAN and other LAA occluders. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 435-446.	2.3	8
131	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE-AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1372-1382.	1.2	111
132	Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies. <i>Pharmacoeconomics</i> , 2017, 35, 67-75.	1.7	6
133	Comparison of health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis protocol. <i>BMJ Open</i> , 2017, 7, e017577.	0.8	5
134	Left atrial appendage closure using AMPLATZER,® devices: A large, multicenter, Italian registry. <i>International Journal of Cardiology</i> , 2017, 248, 103-107.	0.8	51

#	ARTICLE	IF	CITATIONS
135	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017, 7, e015099.	0.8	37
136	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-analysis From the PREFER in AF (Prevention of Thromboembolism and Bleeding in Atrial Fibrillation) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, e007187.	1.6	187
137	Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	2
138	Changes in Oral Anticoagulant Prescribing for Stroke Prevention in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 1133-1138.	0.7	30
139	Pharmacological stroke prevention in the elderly with atrial fibrillation in Poland – Results of PolSenior study. <i>Neurologia i Neurochirurgia Polska</i> , 2017, 51, 382-387.	0.6	1
140	Atrial fibrillation: catheter ablation. <i>British Journal of Cardiac Nursing</i> , 2017, 12, 200-202.	0.0	0
141	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. <i>Advances in Therapy</i> , 2017, 34, 2043-2057.	1.3	17
142	Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1437-1447.	0.8	7
144	Atrial fibrillation and use of antithrombotic medications in older people: A population-based study. <i>International Journal of Cardiology</i> , 2017, 249, 173-178.	0.8	19
145	Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. <i>European Heart Journal</i> , 2017, 38, ehv658.	1.0	142
146	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. <i>Netherlands Heart Journal</i> , 2017, 25, 551-558.	0.3	26
147	Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation. <i>Drugs and Aging</i> , 2017, 34, 701-710.	1.3	19
148	Effectiveness and safety of drugs used for stroke prevention in a cohort of non-valvular atrial fibrillation patients from a primary care electronic database. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 97-107.	0.9	13
149	Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. <i>American Journal of Medicine</i> , 2017, 130, 135-145.	0.6	40
150	Atrial fibrillation in New Zealand primary care: Prevalence, risk factors for stroke and the management of thromboembolic risk. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 311-319.	0.8	28
151	Atrial high-rate episodes and stroke prevention. <i>Europace</i> , 2017, 19, 169-179.	0.7	84
152	Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2376-2388.	1.8	84
153	Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) Study. <i>Journal of the American Heart Association</i> , 2017, 6, e007187.	1.6	187

#	ARTICLE	IF	CITATIONS
154	The management of acute venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1326-1337.	1.8	74
156	The use status of anticoagulation drugs for inpatients with nonvalvular atrial fibrillation in Southwest China. <i>International Journal of General Medicine</i> , 2017, Volume 10, 69-77.	0.8	9
157	Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries. <i>Stroke Research and Treatment</i> , 2017, 2017, 1-12.	0.5	48
158	Non-valvular atrial fibrillation: impact of apixaban on patient outcomes. <i>Patient Related Outcome Measures</i> , 2017, Volume 8, 121-131.	0.7	6
159	Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 289.	0.7	16
160	A Five Year Audit of DC Cardioversion for Patients with Atrial Fibrillation in East London. <i>Journal of Universal Surgery</i> , 2017, 04, .	0.1	0
161	Catheter Ablation of Atrial Fibrillation: Where Are We?. <i>Cardiovascular Innovations and Applications</i> , 2017, 2, .	0.1	0
162	Four-factor prothrombin complex concentrates: effectiveness in the reversal of anticoagulation. <i>International Journal of Clinical Transfusion Medicine</i> , 2017, Volume 5, 39-47.	0.8	2
163	The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy. <i>European Heart Journal</i> , 2018, 39, 2997-2999.	1.0	3
164	Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from <scp>FANTASIA</scp> Registry. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12910.	1.7	5
165	Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 97-111.	1.0	10
166	Quality of oral anticoagulation with vitamin K antagonists in "real-world"™ patients with atrial fibrillation: a report from the prospective multicentre FANTASIA registry. <i>Europace</i> , 2018, 20, 1435-1441.	0.7	39
167	Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 251-258.	1.0	3
168	Effect of Electrophysiology Assessment on Mortality and Hospitalizations in Patients With New-Onset Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 121, 830-835.	0.7	2
169	Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1394-1403.	1.0	52
170	Thromboembolism and Mortality in the Tasmanian Atrial Fibrillation Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 329-336.	1.0	2
171	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	0.8	38
172	Strokeâ€prevention strategies in North American patients with atrial fibrillation: The GLORIAâ€AF registry program. <i>Clinical Cardiology</i> , 2018, 41, 744-751.	0.7	19

#	ARTICLE	IF	CITATIONS
173	Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. <i>Heart</i> , 2018, 104, 1608-1614.	1.2	14
174	Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. <i>Europace</i> , 2018, 20, 243-252.	0.7	33
176	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 74-84.	0.7	21
177	Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 85-94.	0.7	29
178	Special Problems in Management of Atrial Fibrillation in the Elderly. , 2018, , 237-250.		0
181	Diagnostics, treatment and secondary prevention of ischemic stroke in the Silesian Province, Poland between 2009 and 2015. <i>Neurologia i Neurochirurgia Polska</i> , 2018, 52, 235-242.	0.6	2
183	Left-Atrial Appendage Occluders. , 2018, , 515-533.		0
184	Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation – The Fushimi AF Registry. <i>Circulation Journal</i> , 2018, 82, 2983-2991.	0.7	16
185	The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1412-1425.	0.8	10
186	Does Left Atrial Appendage Amputation During Routine Cardiac Surgery Reduce Future Atrial Fibrillation and Stroke?. <i>Current Cardiology Reports</i> , 2018, 20, 99.	1.3	7
187	Risk Factor Management in Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2018, 7, 118.	1.3	95
188	Re-gaining confidence in contemporary dronedarone use. <i>International Journal of Cardiology</i> , 2018, 264, 97-98.	0.8	2
189	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 27-35.	1.8	15
190	Sex and Stroke Risk in Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 615-617.	1.3	3
191	Strengths and weaknesses of “real-world” studies involving non-vitamin K antagonist oral anticoagulants. <i>Open Heart</i> , 2018, 5, e000788.	0.9	86
192	Comparing Management and Outcomes in Men and Women With Nonvalvular Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 604-614.	1.3	8
193	Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	24
194	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018, 72, 141-153.	1.2	48

#	ARTICLE	IF	CITATIONS
195	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. <i>International Journal of Cardiology</i> , 2018, 270, 160-166.	0.8	24
196	Risk Factors, Co-Morbidities and Treatment of In-Hospital Patients with Atrial Fibrillation in Bulgaria. <i>Medicina (Lithuania)</i> , 2018, 54, 34.	0.8	4
197	Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!. <i>Netherlands Heart Journal</i> , 2018, 26, 334-340.	0.3	5
198	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.4	718
199	Mechanisms and Drug Development in Atrial Fibrillation. <i>Pharmacological Reviews</i> , 2018, 70, 505-525.	7.1	67
200	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. <i>Europace</i> , 2019, 21, 421-427.	0.7	10
201	Exploring the Quality of Anticoagulant Prescribed for Patients With Atrial Fibrillation at the St John of God Hawkesbury District Health Centre, New South Wales, Australia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 46-53.	1.0	3
202	Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. <i>Heart</i> , 2019, 105, 27-33.	1.2	87
203	Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007604.	1.4	10
204	Adverse clinical events in Japanese atrial fibrillation patients with and without coronary artery disease—findings from the SAKURA AF Registry. <i>Current Medical Research and Opinion</i> , 2019, 35, 2053-2062.	0.9	7
205	Prevalence of atrial fibrillation and stroke risk assessment based on telemedicine screening tools in a primary healthcare setting. <i>European Journal of Internal Medicine</i> , 2019, 67, 36-41.	1.0	19
206	A Narrative Review of Nonvitamin K Antagonist Oral Anticoagulant Use in Secondary Stroke Prevention. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2363-2375.	0.7	4
207	Baseline Demographics and Clinical Characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. <i>Circulation Journal</i> , 2019, 83, 1538-1545.	0.7	42
208	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	0.6	8
209	Antithrombotic therapy in acute coronary syndrome and stable coronary artery disease patients with atrial fibrillation: a 3-year retrospective cohort study. <i>Personalized Medicine</i> , 2019, 16, 399-407.	0.8	0
210	Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management. <i>Journal of Human Hypertension</i> , 2019, 33, 824-836.	1.0	55
211	<p>Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 429-437.	1.0	1
212	Esmolol Compared with Amiodarone in the Treatment of Recent-Onset Atrial Fibrillation (RAF): An Emergency Medicine External Validity Study. <i>Journal of Emergency Medicine</i> , 2019, 56, 308-318.	0.3	6

#	ARTICLE	IF	CITATIONS
213	Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study. <i>Future Cardiology</i> , 2019, 15, 109-118.	0.5	3
214	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019, 132, 749-757.e5.	0.6	48
215	Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Scoreâ€“Matched Cohort Study. <i>Clinical Therapeutics</i> , 2019, 41, 1598-1604.	1.1	26
216	Is anticoagulant therapy always indicated in â€œmedium-riskâ€œ patients with first diagnosed atrial fibrillation? Insights from a real world, 10-year observational study. <i>International Journal of Cardiology</i> , 2019, 288, 76-81.	0.8	0
217	Atrial fibrillation ablation in practice: assessing CABANA generalizability. <i>European Heart Journal</i> , 2019, 40, 1257-1264.	1.0	105
218	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019, 9, e022478.	0.8	50
219	Potential missed opportunities to prevent ischaemic stroke: prospective multicentre cohort study of atrial fibrillation-associated ischaemic stroke and TIA. <i>BMJ Open</i> , 2019, 9, e028387.	0.8	3
220	Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City. <i>Rational Pharmacotherapy in Cardiology</i> , 2019, 15, 43-48.	0.3	3
221	Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study. <i>BMJ Open</i> , 2019, 9, e031678.	0.8	6
222	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. <i>Acta Cardiologica</i> , 2019, 74, 309-318.	0.3	16
223	Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 223-230.	0.7	4
224	Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 86-93.	1.0	7
225	Trends in preadmission oral anticoagulant use and clinical outcome in atrial fibrillation patients admitted with acute stroke in Denmark. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 112-120.	1.8	4
226	Clinical benefits and risks of antithrombotic therapy in patients with atrial fibrillation with comorbidities â€“ A report from the CHART-2 Study. <i>International Journal of Cardiology</i> , 2020, 299, 160-168.	0.8	4
227	Prevalence and risk factors of left atrial thrombus in patients with atrial fibrillation and lower class (IIa) recommendation to anticoagulants. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 717-724.	0.7	5
228	Cost and burden of poor anticoagulation control with vitamin K antagonists in patients with nonvalvular atrial fibrillation in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 74, 773-780.	0.4	1
229	Cause cardiache di embolia cerebrale. <i>EMC - Neurologia</i> , 2020, 20, 1-19.	0.0	0
230	Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark (1996â€“2016). <i>Neurology</i> , 2020, 95, e2343-e2353.	1.5	20

#	ARTICLE	IF	CITATIONS
231	Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3987.	1.0	15
232	Anticoagulant Initiation During Hospital Admissions for Atrial Fibrillation in South-East Queensland, Australia. <i>Heart Lung and Circulation</i> , 2020, 29, e222-e230.	0.2	5
233	Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen. <i>Journal of Cardiology</i> , 2020, 76, 35-43.	0.8	5
234	Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study. <i>International Journal of Clinical Practice</i> , 2020, 74, e13589.	0.8	6
235	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020, 318, 67-73.	0.8	11
236	Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A population-based study. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1356-1363.	0.8	4
237	Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation—the REFLEC-CR Study. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 383-389.	1.3	1
238	Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2020.	1.0	5
239	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Catheter Ablation or Antiarrhythmic Drug Therapy: A Systematic Review and Meta-analysis. <i>CJC Open</i> , 2020, 2, 286-295.	0.7	8
240	Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. <i>CardioRenal Medicine</i> , 2020, 10, 266-276.	0.7	14
241	Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry. <i>Thrombosis Journal</i> , 2020, 18, 5.	0.9	6
242	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 229-237.	1.8	16
243	Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f101-f110.	1.4	14
244	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
245	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	1.0	4
246	STRUCTURAL AND FUNCTIONAL PARAMETERS OF THE CARDIOVASCULAR SYSTEM DURING ATRIAL FIBRILLATION IN PATIENTS AFTER STROKE. <i>Wiadomości Lekarskie</i> , 2021, 74, 465-470.	0.1	0
247	Symptom management strategies: Rhythm vs rate control in patients with atrial fibrillation in the Balkan region: Data from the BALKAN-AF survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14080.	0.8	3
248	Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective. <i>Clinical Drug Investigation</i> , 2021, 41, 255-267.	1.1	11

#	ARTICLE	IF	CITATIONS
249	Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues. <i>Hamostaseologie</i> , 2021, 41, 035-041.	0.9	1
250	Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients. <i>Cardiology Research and Practice</i> , 2021, 2021, 1-8.	0.5	0
251	The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 93-100.	0.7	2
252	Preclinical assessment of a modified Occlutech left atrial appendage closure device in a porcine model. <i>Scientific Reports</i> , 2021, 11, 2988.	1.6	7
253	Epidemiological characteristics, management, and outcomes of atrial fibrillation in <sc>TUNISIA</sc>: Results from the National Tunisian Registry of Atrial Fibrillation (<sc>NATUREâ€AF</sc>). <i>Clinical Cardiology</i> , 2021, 44, 501-510.	0.7	7
254	Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 221-236.	0.6	2
256	Genetics of atrial fibrillationâ€”practical applications for clinical management: if not now, when and how?. <i>Cardiovascular Research</i> , 2021, 117, 1718-1731.	1.8	11
257	Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4747-4755.	1.1	3
259	Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021, 10, 2866.	1.0	5
261	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006852.	0.9	11
262	Quality indicators in the management of atrial fibrillation: the BALKAN-AF survey. <i>International Journal of Cardiology</i> , 2021, 333, 105-109.	0.8	2
263	Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. <i>American Heart Journal</i> , 2021, 236, 59-68.	1.2	7
264	Rivaroxaban in patients with atrial fibrillation: from research to real practice (based on REGistry of Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 0.1)	0.1	0
265	The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>TH Open</i> , 2021, 05, e353-e362.	0.7	5
267	Quality indicators in the management of elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 651-658.	1.8	8
268	Direct Oral Anticoagulants and Non-valvular Atrial Fibrillation: Compliance with Dose Level Guidelines in Patients Aged 80 Years and Over. <i>Drugs and Aging</i> , 2021, 38, 939-950.	1.3	2
270	Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. <i>Europace</i> , 2022, 24, 552-564.	0.7	22
271	Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 994-1009.	1.1	2

#	ARTICLE	IF	CITATIONS
272	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	1.4	6
273	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
274	Epidemiology and long-term prognosis of atrial fibrillation in rural African patients. <i>Egyptian Heart Journal</i> , 2019, 71, 6.	0.4	7
275	Stroke Prevention in Atrial Fibrillation – Outcomes and Future Directions. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 194.	1.3	2
276	Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i>	0.3	7
277	Antithrombotic Therapy in Patients with Recent Stroke and Atrial Fibrillation. <i>Current Pharmaceutical Design</i> , 2020, 26, 2715-2724.	0.9	1
278	The Health Buddies App as a Novel Tool to Improve Adherence and Knowledge in Atrial Fibrillation Patients: A Pilot Study. <i>JMIR MHealth and UHealth</i> , 2017, 5, e98.	1.8	43
279	A comprehensive insight of novel antioxidant therapies for atrial fibrillation management. <i>Drug Metabolism Reviews</i> , 2015, 47, 388-400.	1.5	13
280	Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain. <i>Journal of Health Economics and Outcomes Research</i> , 2016, 4, 19-34.	0.6	9
281	Left atrial appendage occlusion for stroke prevention – state of the art as provided in an updated EHRA/EAPCI consensus statement and future perspectives. <i>EuroIntervention</i> , 2020, 15, 1117-1119.	1.4	6
282	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. <i>EuroIntervention</i> , 2015, 10, 1109-1125.	1.4	76
283	Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 211-219.	0.3	7
284	The Cumulative Incidence of Stroke, Myocardial infarction, Heart Failure and Sudden Cardiac Death in Patients with Atrial Fibrillation. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2017, 71, 316.	0.4	11
285	Management of arrhythmia in sepsis and septic shock. <i>Anaesthesiology Intensive Therapy</i> , 2017, 49, 419-429.	0.4	25
286	Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center. <i>Cardiology Journal</i> , 2015, 22, 296-305.	0.5	3
287	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention. <i>Cardiology Journal</i> , 2019, , .	0.5	3
288	Mechanisms of ST-segment elevation myocardial infarction in patients with atrial fibrillation, prior stenting and long-standing chronic coronary syndrome. <i>Cardiology Journal</i> , 2020, 27, 8-15.	0.5	5
289	New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience. <i>Kardiologia Polska</i> , 2015, 73, 85-93.	0.3	2

#	ARTICLE	IF	CITATIONS
290	Experience with various occluder types for endovascular hemodynamic isolation of the left atrium appendage in patients with non-valvular atrial fibrillation. <i>Journal of Arrhythmology</i> , 2021, 28, 45-54.	0.1	2
291	Comparison between Amulet and Watchman left atrial appendage closure devices: A real-world, single center experience. <i>IJC Heart and Vasculature</i> , 2021, 37, 100893.	0.6	9
292	Treatment of atrial fibrillation in the coronary artery bypass surgery: clinical significance and the selection of the surgical procedures. <i>Journal of the Japanese Coronary Association</i> , 2015, 21, 246-252.	0.0	0
293	Non Valvular Atrial Fibrillation Related Ischaemic Stroke at the Teaching Hospital of Yalgado OuÃ©draogo, Burkina Faso. <i>Journal of Vascular Medicine & Surgery</i> , 2015, 03, .	0.1	2
294	Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement. <i>Drugs in Context</i> , 2016, 5, 1-6.	1.0	3
295	Background: Stroke Prevention in Patients with Atrial Fibrillation. , 2017, , 1-12.		0
296	Thromboembolism and bleeding risk scores and predictors of cardiac death in a population with atrial fibrillation. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 109, 5-13.	0.3	5
297	ANALYSIS OF ANTICOAGULATION THERAPY IN ATRIAL FIBRILLATION IN OUTPATIENT PRACTICE. , 2018, 66, 28-31.		0
298	2018 Korean Heart Rhythm Society Guidelines for The Rate Control of Atrial Fibrillation. <i>Korean Journal of Medicine</i> , 2018, 93, 133-139.	0.1	2
299	CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. <i>Translational Medicine</i> , 2019, 5, 10-22.	0.1	0
300	Scoring systems stratifying the risk of bleeding, thromboembolism in patients with atrial fibrillation and haemorrhagic shock of the patient with triple therapy. <i>Interni Medicina Pro Praxi</i> , 2019, 21, 100-104.	0.0	0
302	Efficacy and safety of direct oral anticoagulants and warfarin in atrial fibrillation patients as part of multicomponent antithrombotic therapy. <i>Kardiologicheskii Vestnik</i> , 2020, , 46-56.	0.1	1
303	Role of the autonomic nervous system in atrial fibrillation pathogenesis. <i>Russian Journal of Cardiology</i> , 2020, 25, 3663.	0.4	6
304	Clinical features of atrial fibrillation in obese hypertensives: results of a retrospective observational study. <i>Arterial Hypertension (Russian Federation)</i> , 2020, 26, 391-399.	0.1	3
305	Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2. <i>Russian Journal of Cardiology</i> , 2020, 25, 4179.	0.4	1
306	Atrial fibrillation and dementia: an unresolved â€˜Folie Ã© Deuxâ€™™. <i>Open Heart</i> , 2020, 7, e001087.	0.9	1
307	Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1672-1682.	1.3	1
308	Precise Drug Sequential Therapy Can Improve the Cardioversion Rate of Atrial Fibrillation with Valvular Disease after Radiofrequency Ablation. <i>Methods in Molecular Biology</i> , 2020, 2204, 145-159.	0.4	0

#	ARTICLE	IF	CITATIONS
309	Modern aspects of surgical treatment of patients with atrial fibrillation. Development of uniform criteria for selecting patients for radiofrequency ablation. Meditsinskiy Sovet, 2020, , 58-64.	0.1	0
310	Clinical discussions in antithrombotic therapy management : a delphi consensus panel. Journal of Atrial Fibrillation, 2020, 12, 2159.	0.5	1
311	Combination of Atrial Fibrillation and Coronary Heart Disease in Patients in Clinical Practice: Comorbidities, Pharmacotherapy and Outcomes (Data from the RED;VASA Registries). Rational Pharmacotherapy in Cardiology, 2021, 17, 702-711.	0.3	2
312	Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry. ESC Heart Failure, 2020, 7, 3821-3829.	1.4	3
314	Value of cystatin C in predicting atrial fibrillation recurrence after radiofrequency catheter ablation. Journal of Geriatric Cardiology, 2018, 15, 725-731.	0.2	1
315	Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORPâ€AF Longâ€term General Registry. European Journal of Clinical Investigation, 2021, , e13709.	1.7	0
316	Temporary Trends Concerning the Extent and Efficacy of Atrial Fibrillation Ablation Using Radiofrequency Energy in a Polish Single-Center Experience. Medicina (Lithuania), 2022, 58, 187.	0.8	0
317	Atrial Fibrillation: The Year of 2021 in Review. Journal of Innovations in Cardiac Rhythm Management, 2022, 13, 4847-4851.	0.2	3
318	Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary interventions. Complex Issues of Cardiovascular Diseases, 2022, 11, 98-106.	0.3	0
319	Barriers to prescribing oral anticoagulants to inpatients aged 80 years and older with nonvalvular atrial fibrillation: a cross-sectional study. BMC Geriatrics, 2022, 22, 263.	1.1	4
320	More obvious association between short-term ambient nitrogen dioxide and atrial fibrillation outpatient visits in cool seasons: A hospital-based study in northwestern China. Environmental Research, 2022, 212, 113220.	3.7	3
323	Sex-Differences in Atrial Fibrillation Patients: Bias or Proper Management?. Vascular Health and Risk Management, 2022, Volume 18, 347-358.	1.0	4
324	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2022, 79, 1932-1948.	1.2	63
325	Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. PLoS Medicine, 2022, 19, e1004003.	3.9	10
326	Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries. Journal of Clinical Medicine, 2022, 11, 3751.	1.0	5
327	Association of Concomitant Coronary Artery Disease With Cardiovascular Events in Patients With Atrial Fibrillationâ€• The Fushimi AF Registry â€•. Circulation Journal, 2022, 86, 1252-1262.	0.7	2
328	Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank. Heart, 2022, 108, 1873-1880.	1.2	14
330	Nine-Year Trends in Atrial Fibrillation Prevalence among Romanian Adult Hypertensives: A Post-Hoc Analysis of SEPHAR II-IV Surveys. International Journal of Environmental Research and Public Health, 2022, 19, 9250.	1.2	4

#	ARTICLE	IF	CITATIONS
331	Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit. <i>IJC Heart and Vasculature</i> , 2022, 42, 101117.	0.6	1
332	EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. <i>Eurasian Heart Journal</i> , 2019, , 4-85.	0.2	13
334	Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation. <i>World Journal of Cardiology</i> , 0, 14, 576-598.	0.5	1
335	Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists. <i>Global Cardiology Science & Practice</i> , 2022, 2022, .	0.3	0
336	Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2023, 16, .	2.1	6
337	Benefits of early rhythm control of atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2023, , .	2.3	5
349	False normalisation of Antithrombin in Type II-Heparin Binding Site defects in DOAC treated patients. <i>Hamostaseologie</i> , 2024, , .	0.9	0